Adaptimmune Therapeutics plc

DB:473A Stock Report

Market Cap: €142.3m

Adaptimmune Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

DB:473A Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Jun 24Sell€21,242Cintia PiccinaIndividual24,531€0.87
17 Jan 24Sell€14,635John LungerIndividual22,795€0.73
17 Jan 24Sell€15,127William C. BertrandIndividual23,589€0.73
17 Jan 24Sell€25,417Adrian G. RawcliffeIndividual39,384€0.73
17 Jan 24Sell€12,993Elliot NorryIndividual20,563€0.73
12 Jan 24Sell€22,552Adrian G. RawcliffeIndividual29,202€0.78
12 Jan 24Sell€9,132Elliot NorryIndividual11,808€0.78
12 Jan 24Sell€7,124John LungerIndividual9,229€0.78
12 Jan 24Sell€7,124William C. BertrandIndividual9,229€0.78

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 473A?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,737,7420.679%
VC/PE Firms17,079,7786.67%
Institutions57,534,28922.5%
Hedge Funds63,203,96024.7%
General Public116,327,43845.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.7%.


Top Shareholders

Top 25 shareholders own 53.2% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.7%
EcoR1 Capital, LLC
27,404,070€15.2m0%0.57%
8.79%
Matrix Capital Management Company, LP
22,500,000€12.5m-40.3%0.56%
6.67%
New Enterprise Associates, Inc.
17,079,778€9.5m0%0.52%
6.56%
Baillie Gifford & Co.
16,775,860€9.3m10.7%no data
5.2%
Long Focus Capital Management LLC
13,299,890€7.4m7.72%0.72%
3.91%
PFM Health Sciences, LP
10,000,787€5.6m-4.94%0.4%
2.17%
MPM BioImpact LLC
5,555,461€3.1m0%2.65%
1.99%
BioImpact Capital LLC
5,095,912€2.8m0%0.53%
1.82%
Bank of America Corporation, Asset Management Arm
4,652,325€2.6m0%no data
0.95%
Rock Springs Capital Management LP
2,425,468€1.3m0%0.05%
0.66%
Morgan Stanley, Investment Banking and Brokerage Investments
1,698,740€944.7k286%no data
0.65%
Renaissance Technologies LLC
1,656,575€921.2k-7.26%no data
0.62%
Impresa Management LLC
1,578,783€878.0k0%0.53%
0.39%
JP Morgan Asset Management
986,051€548.4k28.1%no data
0.29%
U.S. Global Investors, Inc.
752,458€418.4k0%0.03%
0.28%
Redmile Group, LLC
715,607€398.0k0%0.02%
0.28%
Millennium Management LLC
715,350€397.8k-8.24%no data
0.27%
Garry Menzel
686,295€381.7k0%no data
0.2%
Marshall Wace LLP
522,608€290.6k261%no data
0.17%
Rathbones Investment Management Limited
432,818€240.7k0%no data
0.16%
State Street Global Advisors, Inc.
396,792€220.7k1.51%no data
0.13%
Dafna Capital Management, LLC
341,064€189.7k0%0.05%
0.12%
Helen Tayton-Martin
300,060€166.9k0%no data
0.11%
BlackRock, Inc.
283,626€157.7k46.4%no data
0.11%
Mercer Investments LLC
273,048€151.8k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 05:30
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Adaptimmune Therapeutics plc is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Ying HuangBofA Global Research
Olga SmolentsevaBryan Garnier & Co